Members of the Sackler family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion to settle lawsuits over the toll of the powerful prescription painkiller.

McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia.

Harvard University has decided against removing from campus buildings the name of a family whose company makes the powerful painkiller OxyContin, despite protest from parents whose children fatally overdosed.

The Supreme Court has rejected a settlement for OxyContin maker Purdue Pharma and members of the Sackler family who own the company.

A company that helped develop marketing campaigns for OxyContin and other opioids has agreed to a $350 million settlement with U.S. states over the toll of the powerful prescription painkillers.

Consulting firm McKinsey and Co. has agreed to pay $78 million to settle claims from insurers and health care funds that its marketing work with Purdue Pharma helped fuel an opioid addiction crisis.

The Supreme Court is wrestling with a nationwide settlement with OxyContin maker Purdue Pharma that would shield members of the Sackler family who own the company from civil lawsuits over the toll of opioids.

The legality of an agreement by the maker of OxyContin to settle thousands of lawsuits over the harm done by opioids is going before the Supreme Court.

The Supreme Court has temporarily blocked a nationwide settlement with OxyContin maker Purdue Pharma that would shield members of the Sackler family who own the company from civil lawsuits over the toll of opioids.

More than a year after the maker of OxyContin reached a tentative settlement over the toll of opioids, the money isn't flowing yet.

Texas lawmakers want tougher criminal penalties for possession of delta-8 and fentanyl. But that would mean much more work for the crime labs handling most of the drug testing for the state’s 254 counties.

The Biden administration is moving to require patients see a doctor in person before getting drugs to treat attention deficit disorders or addictive painkillers, toughening access amid a deepening opioid crisis.

A sense of closure is mixing with anger and pain for some of the nearly two dozen people who told their personal stories to members of the family that owns OxyContin maker Purdue Pharma.

A hearing in U.S. Bankruptcy Court has given survivors of opioid addiction and people who lost loved ones to the crisis the chance to confront members of the family behind OxyContin maker Purdue Pharma.

Addiction and overdose survivors and those who have lost loved ones have unleashed their emotions on members of the family they blame for fueling the opioid epidemic.

A judge has indicated he is moving forward with a plan for the owners of OxyContin maker Purdue Pharma to pump at least another $1.2 billion into a nationwide settlement of lawsuits against over the toll of opioids.

OxyContin maker Purdue Pharma has reached a nationwide settlement over its role in the opioid crisis.

Lawyers for a handful of states say members of the Sackler family who own OxyContin maker Purdue Pharma are abusing the bankruptcy process.

Objections to a historic settlement with Purdue Pharma are mounting in the form of appeals.

A judge formally approved a plan Friday to turn OxyContin maker Purdue Pharma into a new company no longer owned by members of the Sackler family and with its profits going to fight the opioid epidemic.

A landmark settlement in the nation’s opioid epidemic is forcing the owners of OxyContin maker Purdue Pharma to give up the company and pay out $4.5 billion.

A federal bankruptcy judge has approved with conditions a historic opioid settlement between Purdue Pharma and thousands of local and state governments.

A Purdue Pharma lawyer says states would get more money from settling with the company than if they were allowed to continue their lawsuits against the OxyContin maker and members of the Sackler family who own it.

Several U.S. senators are questioning the Food and Drug Administration’s work with a consulting firm that helped businesses sell prescription painkillers during the nation’s overdose crisis.

A member of the family that owns Purdue Pharma has once again stopped short of offering an apology or acknowledgment of responsibility in the opioid crisis.

Purdue Pharma's quest to settle thousands of lawsuits over OxyContin's toll has entered its final phase with the grudging acceptance of most of those who have claims against the company.

A congressional committee has heard grievances against the owners of OxyContin maker Purdue Pharma as it considered legislation that would keep them from using a corporate bankruptcy as a shield for personal liability.

Documentary maker Alex Gibney considers the opioid crisis no accident.

The western state reached the deal after sitting out a multi-state settlement with McKinsey announced in February. The hard bargaining has allowed Nevada to win a settlement that's three and a half times larger than the average settlement with other states. The western state reached the deal after sitting out a multi-state settlement with McKinsey announced in February. The hard bargaining has allowed Nevada to win a settlement that’s three and a half times larger than the average settlement with other states. “Nevada needed and deserved more than what was being made available to us in the multi-state settlement,” state Attorney General Aaron Ford said Monday.

A group of nearly half the state attorneys general said it was disappointed in the plan Purdue filed late Monday night in federal bankruptcy court and some said they would seek changes. Members of the Sackler family who own Purdue would contribute about $4.3 billion. AdCynthia Munger, of Wayne, Pennsylvania, said Purdue's plan is too focused on providing legal protections for members of the Sackler family. On a Facebook Live video Tuesday, Massachusetts Attorney General Maura Healey, a Democrat, said the payment from Sackler family members was too little. AdIn recent letters to a congressional committee, Sackler family members said those who previously served on Purdue's board of directors had combined net assets of $1.1 billion.

The global business consulting firm McKinsey & Company has agreed to a $573 million settlement over its role in the opioid crisis, according to a person with knowledge of the deal. (AP Photo/Toby Talbot, File)The global consulting firm McKinsey & Company agreed to pay nearly $600 million for its role in advising businesses on how to sell more prescription opioid painkillers amid a nationwide overdose crisis. Washington's attorney general announced a separate $13.5 million deal and West Virginia announced a $10 million settlement with the New York-based company. On a video call with journalists Thursday, North Carolina Attorney General Josh Stein said that McKinsey worked for Purdue for 15 years. AdIn a statement, New Jersey Attorney General Gurbir Grewal said that McKinsey would pay out more than it made advising companies on opioid sales.

The global business consulting firm McKinsey & Company has agreed to a $573 million settlement over its role in the opioid crisis, according to a person with knowledge of the deal. Without naming McKinsey, the attorneys general in at least North Carolina and West Virginia have scheduled announcements for Thursday morning regarding the opioid crisis. Purdue agreed to pay $225 million to the U.S. government. Members of the Sackler family who own the company agreed to pay the same amount in a separate settlement announced the same day. The company and family members reached separate agreements with U.S. Justice Department, both announced Oct. 21, 2020.

Members of the family that owns OxyContin maker Purdue Pharma have acknowledged the drug had a role in the opioid crisis but have stopped short of apologizing or admitting wrongdoing. “I want to express my family’s deep sadness about the opioid crisis,” David Sackler, whose family owns Purdue Pharma, said at a rare appearance in a public forum. In contrast to the family members, Purdue CEO Craig Landau testified that the company accepts “full responsibility." The deal leaves open the possibility that family members could be criminally prosecuted. He also noted that about half of what family members took out of the company was paid in taxes.

Two members of the Sackler family who own OxyContin maker Purdue Pharma agreed to appear this week before a congressional committee investigating the family and the company's role in the national opioid addiction and overdose epidemic. The committee scheduled and then canceled a hearing earlier this month after family members would not commit to appearing. Under the deal, family members would also pay at least $3 billion in cash over time. Most Democratic state attorneys general oppose the settlement, saying they want more accountability for Sackler family members. The agreement did not result in criminal claims against Sackler family members, but left open the possibility that some could be brought.

The guilty pleas were entered by Purdue board chairperson Steve Miller on behalf of the company. They were part of a criminal and civil settlement announced last month between the Stamford, Connecticut-based company and the Justice Department. No criminal charges have been filed against family members, although their deal leaves open the possibility of that in the future. The attorneys general for about half the states opposed the federal settlement, as well as the company’s proposed settlement in bankruptcy court. In the bankruptcy case, Purdue has proposed transforming into a public benefit corporation with its proceeds going to help address the opioid crisis.

The Justice Department says on Wednesday, Purdue Pharma, the company that makes OxyContin, will plead guilty to three federal criminal charges as part of a settlement of more than $8 billion. The deal does not release any of the company’s executives or owners — members of the wealthy Sackler family — from criminal liability, and a criminal investigation is ongoing. Family members said they acted “ethically and lawfully,” but some state attorneys general said the agreement fails to hold the Sacklers accountable. Purdue will make a direct payment to the government of $225 million, which is part of a larger $2 billion criminal forfeiture. Until recently, the Sackler name was on museum galleries and educational programs around the world because of gifts from family members.

In a series of non-binding votes, the FDA experts said that the updated OxyContin appeared to cut down abuse via snorting and injecting, compared to the original drug. But panelists overwhelmingly ruled that data from Purdue and other researchers did not show that the reformulation curbed abuse overall or led to fewer overdoses. Panelists said the shortcomings were due, in part, to the challenges of studying overdoses, which often involve multiple drugs. Purdue’s 2010 revamped OxyContin was the first of several opioids developed by drugmakers to help curb abuse. Purdue said in a statement following the meeting it would continue to work with the FDA as it reviewed the OxyContin studies.